After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer
pharmaphorum
DECEMBER 23, 2022
This alone causes expense for cash-strapped hospitals and puts pressure on nursing and medical staff while they manage the side effects. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Side effects and cost implications.
Let's personalize your content